Previous Close | 0.3470 |
Open | 0.3484 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's Range | 0.3300 - 0.4000 |
52 Week Range | 0.3250 - 2.6000 |
Volume | |
Avg. Volume | 522,687 |
Market Cap | 10.841M |
Beta (5Y Monthly) | 0.27 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.7700 |
Earnings Date | Dec 12, 2024 - Dec 16, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 6.00 |
VICTORIA, British Columbia, November 13, 2024--ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ: IPA), a leader in AI-driven medical innovation, is proud to announce a significant breakthrough in its primary cancer research initiatives. This accomplishment not only highlights IPA’s cutting-edge discovery and AI capabilities, but it also strategically places the company in the rapidly growing market for these cancer-combating antibodies, which is projected to reach $20.7 billion by
VICTORIA, British Columbia, November 04, 2024--ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, announces the details of its upcoming TECHDAY event on Friday, November 15, 2024, from 9:00 a.m. to 12:30 p.m. EST in Cambridge, Massachusetts. This exclusive gathering will highlight IPA’s latest advancements in AI-driven design, biologics innovation, and strategic technological developments.